By M. Marin
NASDAQ: SBC
READ THE FULL SBC RESEARCH REPORT
Company founder reduced stake from ~85% to ~82%
SBC Medical Group Holdings (NASDAQ: SBC) provides end-to-end solutions enabling aesthetics clinics to launch, expand, and/or operate their businesses. In recent months, the company’s goal has been to improve the trading liquidity of its shares. Consistent with this goal, SBC facilitated a secondary offering of about 3.1 million SBC shares by the company’s founder, Dr. Yoshiyuki Aikawa. The offering was priced at $3.25 per share. The underwriters also have a 45-day option to purchase up to an additional 465k SBC shares.
Prior to the secondary, Dr. Aikawa beneficially controlled about 85% of the voting power of SBC. Following the offering, he controls about 82%. We view this change as a positive. Given the founder’s sizable stake, a reduction in the number of shares held by Dr. Aikawa in order to inject more shares into public float could be a positive measure for share liquidity, in our view. We note, however, that SBC remains a control company. SBC has indicated that, as its largest shareholder, Dr. Aikawa is committed to the company's growth objectives.
There were no proceeds to SBC from the offering, as the company did not sell shares. SBC has a strong balance sheet, with a solid cash balance and minimal debt. The company ended 2025 with cash and equivalents of $163.8 million, compared to $127.4 million at year-end 2024. This is expected to give SBC the flexibility to pursue strategic growth opportunities. The company intends to allocate available capital to organic and strategic M&A investments in Japan and internationally. SBC’s strategy is to focus on expanding its clinic network, enhancing its technology capabilities, developing new services, and pursuing strategic partnership or acquisitions to complement and enhance organic growth prospects.
SBC implemented a number of measures in 2025 that appear to be lifting operating results and mirror organic growth, complemented by strategic M&A. For example, in April 2025, the company revised its franchise fee structure to make it easier financially for franchisees to join its network and, as they ramp up services and customer bases, pay fees based on a tiered fee system that aligns with the scale. As SBC expected, this contributed to improving cost efficiencies achieved by 2H25,
In addition, SBC launched a multi-brand strategy in aesthetic dermatology and other areas to address the increasingly diverse needs of its growing customer base to customize services across multiple brands, segment the market, and garner more market share overall. SBC has also increased its focus on many non-aesthetic specialties where it believes it has substantial opportunities to grow and gain more market share. Reflecting these and other changes and improved product mix, average revenue per customer visit has begun to recover and improve. The company expects efforts will continue to diversify revenue sources. SBC also sees international expansion, focused on the U.S. and Southeast Asia, as integral to creating long-term value. By 2027, the company expects to operate a significantly larger global footprint offering diversified medical services, with an emphasis on aesthetic medicine.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.